Logo image of CREX

CREATIVE REALITIES INC (CREX) Stock Fundamental Analysis

NASDAQ:CREX - Nasdaq - US22530J3095 - Common Stock - Currency: USD

1.88  -0.06 (-3.09%)

Fundamental Rating

2

Overall CREX gets a fundamental rating of 2 out of 10. We evaluated CREX against 97 industry peers in the Media industry. CREX may be in some trouble as it scores bad on both profitability and health. CREX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

In the past year CREX has reported negative net income.
In the past year CREX had a positive cash flow from operations.
In multiple years CREX reported negative net income over the last 5 years.
In multiple years CREX reported negative operating cash flow during the last 5 years.
CREX Yearly Net Income VS EBIT VS OCF VS FCFCREX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

1.2 Ratios

CREX has a Return On Assets of -5.38%. This is in the lower half of the industry: CREX underperforms 62.89% of its industry peers.
CREX has a Return On Equity (-13.78%) which is in line with its industry peers.
CREX has a Return On Invested Capital (1.43%) which is in line with its industry peers.
Industry RankSector Rank
ROA -5.38%
ROE -13.78%
ROIC 1.43%
ROA(3y)-2.23%
ROA(5y)-17.47%
ROE(3y)-5.54%
ROE(5y)-80.4%
ROIC(3y)N/A
ROIC(5y)N/A
CREX Yearly ROA, ROE, ROICCREX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

CREX has a Operating Margin (1.84%) which is comparable to the rest of the industry.
CREX's Gross Margin of 47.22% is in line compared to the rest of the industry. CREX outperforms 55.67% of its industry peers.
CREX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 1.84%
PM (TTM) N/A
GM 47.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.36%
GM growth 5Y1.66%
CREX Yearly Profit, Operating, Gross MarginsCREX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CREX is destroying value.
CREX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CREX has more shares outstanding
CREX has a worse debt/assets ratio than last year.
CREX Yearly Shares OutstandingCREX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CREX Yearly Total Debt VS Total AssetsCREX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

CREX has an Altman-Z score of -0.30. This is a bad value and indicates that CREX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CREX (-0.30) is worse than 75.26% of its industry peers.
The Debt to FCF ratio of CREX is 44.58, which is on the high side as it means it would take CREX, 44.58 years of fcf income to pay off all of its debts.
CREX has a Debt to FCF ratio (44.58) which is comparable to the rest of the industry.
CREX has a Debt/Equity ratio of 1.02. This is a high value indicating a heavy dependency on external financing.
CREX has a Debt to Equity ratio of 1.02. This is comparable to the rest of the industry: CREX outperforms 48.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.02
Debt/FCF 44.58
Altman-Z -0.3
ROIC/WACC0.18
WACC7.84%
CREX Yearly LT Debt VS Equity VS FCFCREX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

CREX has a Current Ratio of 0.55. This is a bad value and indicates that CREX is not financially healthy enough and could expect problems in meeting its short term obligations.
CREX's Current ratio of 0.55 is on the low side compared to the rest of the industry. CREX is outperformed by 83.51% of its industry peers.
CREX has a Quick Ratio of 0.55. This is a bad value and indicates that CREX is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.48, CREX is doing worse than 85.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.55
Quick Ratio 0.48
CREX Yearly Current Assets VS Current LiabilitesCREX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.71% over the past year.
The Revenue has grown by 12.59% in the past year. This is quite good.
CREX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.98% yearly.
EPS 1Y (TTM)5.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-235%
Revenue 1Y (TTM)12.59%
Revenue growth 3Y40.23%
Revenue growth 5Y9.98%
Sales Q2Q%-23.83%

3.2 Future

The Earnings Per Share is expected to grow by 51.19% on average over the next years. This is a very strong growth
Based on estimates for the next years, CREX will show a quite strong growth in Revenue. The Revenue will grow by 13.92% on average per year.
EPS Next Y32.77%
EPS Next 2Y51.19%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year9.3%
Revenue Next 2Y13.92%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CREX Yearly Revenue VS EstimatesCREX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
CREX Yearly EPS VS EstimatesCREX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -1 -2 -3

2

4. Valuation

4.1 Price/Earnings Ratio

CREX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CREX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CREX Price Earnings VS Forward Price EarningsCREX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

73.20% of the companies in the same industry are more expensive than CREX, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CREX is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 33.87
EV/EBITDA 6.44
CREX Per share dataCREX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

CREX's earnings are expected to grow with 51.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.19%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

CREX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CREATIVE REALITIES INC

NASDAQ:CREX (4/28/2025, 3:36:41 PM)

1.88

-0.06 (-3.09%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)03-14 2025-03-14/amc
Earnings (Next)05-08 2025-05-08/bmo
Inst Owners19.74%
Inst Owner Change0%
Ins Owners16.24%
Ins Owner Change4.05%
Market Cap19.65M
Analysts84
Price Target6.76 (259.57%)
Short Float %0.24%
Short Ratio0.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.36%
Min EPS beat(2)-140.1%
Max EPS beat(2)158.81%
EPS beat(4)3
Avg EPS beat(4)32.35%
Min EPS beat(4)-140.1%
Max EPS beat(4)158.81%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.05%
Min Revenue beat(2)1.87%
Max Revenue beat(2)4.23%
Revenue beat(4)3
Avg Revenue beat(4)1.52%
Min Revenue beat(4)-2.08%
Max Revenue beat(4)4.23%
Revenue beat(8)3
Avg Revenue beat(8)-4.08%
Revenue beat(12)3
Avg Revenue beat(12)-3.46%
Revenue beat(16)3
Avg Revenue beat(16)-3.09%
PT rev (1m)-8.62%
PT rev (3m)-11.67%
EPS NQ rev (1m)27.38%
EPS NQ rev (3m)-238.89%
EPS NY rev (1m)-341.67%
EPS NY rev (3m)-201.95%
Revenue NQ rev (1m)2.25%
Revenue NQ rev (3m)-19.04%
Revenue NY rev (1m)-7.04%
Revenue NY rev (3m)-7.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.39
P/FCF 33.87
P/OCF 5.81
P/B 0.77
P/tB N/A
EV/EBITDA 6.44
EPS(TTM)-0.33
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)0.06
FCFY2.95%
OCF(TTM)0.32
OCFY17.21%
SpS4.87
BVpS2.44
TBVpS-2.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.38%
ROE -13.78%
ROCE 2.4%
ROIC 1.43%
ROICexc 1.46%
ROICexgc 48.4%
OM 1.84%
PM (TTM) N/A
GM 47.22%
FCFM 1.14%
ROA(3y)-2.23%
ROA(5y)-17.47%
ROE(3y)-5.54%
ROE(5y)-80.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.36%
GM growth 5Y1.66%
F-Score3
Asset Turnover0.78
Health
Industry RankSector Rank
Debt/Equity 1.02
Debt/FCF 44.58
Debt/EBITDA 5.16
Cap/Depr 68.69%
Cap/Sales 5.51%
Interest Coverage 0.78
Cash Conversion 67.4%
Profit Quality N/A
Current Ratio 0.55
Quick Ratio 0.48
Altman-Z -0.3
F-Score3
WACC7.84%
ROIC/WACC0.18
Cap/Depr(3y)115.1%
Cap/Depr(5y)95.1%
Cap/Sales(3y)8.11%
Cap/Sales(5y)6.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-235%
EPS Next Y32.77%
EPS Next 2Y51.19%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.59%
Revenue growth 3Y40.23%
Revenue growth 5Y9.98%
Sales Q2Q%-23.83%
Revenue Next Year9.3%
Revenue Next 2Y13.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year656.75%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-49.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.57%
OCF growth 3Y93.04%
OCF growth 5YN/A